Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Harvard University's Office of Technology Development has signed a multiyear license and sponsored-research agreement with Merck & Co. focused on new osteoporosis therapies. Merck will fund research in the lab of immunology professor Laurie Glimcher. In return, it will get licenses to specific molecules that may result from the work. Glimcher studies the molecular pathways that lead to bone growth and looks for intervention points for enhancing bone formation or preventing osteoporosis in adults. Her lab has already identified several key mediators of bone growth that Merck hopes to use in the development of therapies.
This article has been sent to the following recipient: